文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

立体定向体部放疗能否替代近距离放疗治疗妇科肿瘤?系统综述

Can stereotactic body radiotherapy replace brachytherapy in gynecologic cancers? A systematic review of current evidence.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-07-17

近距离放疗(BT)在瘤内剂量递增和中心剂量不均匀性方面始终更优,SBRT在无 margins 场景下周边靶区覆盖和适形性有竞争力,但应用临床实际计划 margins 后优势减弱。唯一生存分析显示调整预后因素后两技术总生存无显著差异。BT仍是妇科肿瘤剂量递增的参考标准,SBRT可在BT不可行时作为选择性替代。

要点

  • BT在瘤内剂量递增和中心剂量不均匀性方面始终优于SBRT。
  • SBRT在无 margins 场景下周边靶区覆盖和适形性有竞争力,但临床实际 margins 后优势减弱。
  • 唯一生存分析显示调整预后因素后SBRT与BT总生存无显著差异。

核心结论

  • BT仍是妇科肿瘤剂量递增的参考标准,SBRT可在BT不可行时作为选择性替代,但需前瞻性研究明确其临床角色。

主要发现

  • BT始终实现更优的瘤内剂量递增和更高的中心剂量不均匀性。
  • SBRT在无 margins 场景下显示有竞争力的周边靶区覆盖和更优的适形性,但应用临床实际计划 margins 后这些优势减弱。
  • 唯一可用的生存分析报告调整预后因素后两种技术总生存无显著差异。

临床怎么用

  • BT应作为妇科肿瘤剂量递增的首选参考标准。
  • 当BT不可行时,可考虑SBRT作为选择性替代方案。

局限性

  • 纳入研究以剂量学分析为主,仅1项人群队列提供生存数据,缺乏前瞻性标准化计划和长期随访研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brachytherapy (BT) is a cornerstone of curative radiotherapy for gynecologic cancers due to its ability to deliver high intratumoral doses with steep dose gradients. Limited availability and declining utilization have increased interest in stereotactic body radiotherapy (SBRT) as a non-invasive alternative. This systematic review evaluates the current evidence comparing SBRT and BT in gynecologic cancers. A systematic search of PubMed, Scopus, EMBASE, Cochrane Library, and Web of Science was conducted for studies published between 2014 and 2025. Eligible studies included dosimetric analyses, observational cohorts, and consensus statements comparing SBRT and BT. Outcomes of interest were target coverage, intratumoral dose escalation, organ-at-risk exposure, conformity and homogeneity indices, and overall survival when available. Eleven studies met the inclusion criteria, including nine dosimetric studies, one population-based cohort, and one consensus guideline, mainly focused on locally advanced cervical cancer. BT consistently achieved superior intratumoral dose escalation and higher central dose heterogeneity, while SBRT showed competitive peripheral target coverage and improved conformity in margin-free scenarios. These advantages were reduced when clinically realistic planning margins were applied. The only available survival analysis reported no significant difference in overall survival between techniques after adjustment for prognostic factors. BT remains the reference standard for dose escalation in gynecologic cancers. SBRT may be considered a selective alternative when BT is not feasible, but prospective studies with standardized planning and long-term follow-up are needed to define its clinical role.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ruiz PV, Vacas AI, Arenas ÁV, et al. Can stereotactic body radiotherapy replace brachytherapy in gynecologic cancers? A systematic review of current evidence. Clin Transl Radiat Oncol. 2026. PMID: 42540551. doi:10.1016/j.ctro.2026.101226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。